Tectonic Therapeutic Inc. (NASDAQ: TECX) will host a virtual key opinion leader $(KOL)$ event and discussion on TX2100, a novel therapeutic candidate for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT), on Tuesday, February 24, 2026, from 11:00 a.m. to 12:30 p.m. ET. The event will feature presentations from Tectonic’s management team and Hanny Al-Samkari, MD, of Massachusetts General Hospital and Harvard Medical School. Attendees will hear about the mechanistic rationale and preclinical evidence supporting TX2100, a GPCR antagonist, as well as clinical insights into HHT and current unmet medical needs. A live Q&A session will follow the presentations. To register, click here.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tectonic Therapeutic Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9653166-en) on February 11, 2026, and is solely responsible for the information contained therein.